🙏to the authors of this recommendation on novel drug–radiotherapy combinations for quoting our UK CONCORDE trial They urge @NCICTEP_ClinRes and @theNCI to endorse and support similar innovative platform designs in the USA @LeedsCTRU @TheLancetOncol

Great to meet my ctDNA NGS expert colleague @AlastairGreyst2 at #ESMO24 discussing a new UK report on all things ctDNA supported by @Roche. Download it using the QR!

Excellent session highlighting that the UK is leading the way in early-phase trials combining drug-radiotherapy A standout example is the CONCORDE trial ➡️Platform trial incorporating multiple DDR inhibitors ➡️TITE-CRM Bayesian design ➡️Randomised controlled arm @LeedsCTRU @CR_UK

Happy to share Newcastle and Manchester ECMC joint publication looking at access to early phase trials in oncology 📄 https://t.co/aQrxatQgAJ 📌 Inequalities in socioeconomic and geographic factors influence referral and enrolment to early phase clinical trials

@AlastairGreyst2 flying the flag for 🇬🇧 research at #ASCO24 with the outstanding CONCORDE study @finn_corinne

@AshHorne1983 presented the toxicity profile of the calibration arm of the CONCORDE trial @LcsmUk #ESTRO24 ▶️low rates of severe pneumonitis and œsophagites when modern RT techniques and strict dose constraints are applied @AlastairGreyst2 @LeedsCTRU @TheChristieNHS @MCRCnews

Building the team @DrMirallas @myESMO #ESMOTAT24 @sarahaftonrae

Where were you @AdamSharpMedOnc? Need conference running buddies #ESMOTAT24 @sarahaftonrae

Opportunity for PhDs ⁦@NU_Cancer⁩ ⁦@UniofNewcastle⁩ for clinicians interested in cancer. Part of our ⁦@CRUKresearch⁩ funded clinical academic training programme. ⁦@PasRescigno⁩

At @CR_UK we’ve made huge progress on cancer over the last 50 years – but cancer is still the defining health issue of our time. Today we’ve launched our #CancerManifesto outlining the steps the next UK Government must take so that people can live #LongerBetterLives. Visit our

This is is world’s biggest #SABR meeting! Fantastic day one! #radonc #UKSABR23

At the UKLCC Conference, we will be joined by Dr @AlastairGreyst2, who will explore the impact of delays in molecular diagnostics and look to answer how we can speed things up. 💬 Register now for our solutions-focused conference on the 10th November 🎟️ https://t.co/ZGueI8cKqd

Don’t miss the amazing @lauren_henke @Mat_Guc @gerryhanna @AlastairGreyst2 @alison_tree @DanielCagney @DrSuneil_PCa and many more at #UKSABR23 The party also promises to be a treat! Register now https://t.co/zzxv0K1C5Z #radonc #medphys #rtt

Incredibly proud 2 B the CI for this study+working with the amazing @Newcastle_ECMC team -Investigating the impact of a personalised complementary therapy intervention 4 the management of white coat hypertension within @ECMC_UK @CRUKresearch patients @NuTHResearch @NewcastleHosps

Unique opportunity to work in a great environment @sirbobbyrobsonunit #phase1unit @newcastleuni @freemanhospitalncl with the most amazing group of colleagues @OingC1 @AlastairGreyst2 @plummer_ruth

A lovely shout out to staff at @stoswaldsuk Personally very proud to work with the team there, and the joint supportive care clinic @NewcastleHosps @jenny_welford @FlicDewhurst

⁦@gwalls89⁩ ⁦@NICCBeamTeam⁩ ⁦@QubPGJCCR⁩ visiting ⁦@NcccOncology⁩ ⁦@teambeamNCCC⁩ to teach about measuring dose to cardiac substructures; using patients treated on ⁦@LcsmUk⁩ #Concorde trial. Thanks Gerard! @gerryhanna⁩⁦@finn_corinne⁩

🎥@AlastairGreyst2 highlights challenges in solid tumor genomic testing for lung cancer in the UK, proposing solutions for improved diagnosis: ➡️ https://t.co/kF92FCbIIh⬅️ @BTOGORG #BTGO2023 #LungCancer #LCSM

Nomogram will be available

Excellent work showing tumour fraction on cfDNA predicts prognosis for patients referred to early clinical trials. We should confirm/use on Target National @MatthewGKrebs @oncocook @Newcastle_ECMC @ECMC_Manchester